MoonLake Immunotherapeutics reported cash from operations of -$55.56M and free cash flow of -$55.56M for the quarter ended Jun 2026, down 1.9% year over year. This cash flow statement covers 22 quarters of results from Mar 2021 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow Statement | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||||||||
| Net Income | -6.29M | -14.32M | -15.88M | -17.42M | -14.74M | -16.47M | -12.22M | -12.35M | -11.62M | -7.89M | -13.97M | -24.76M | -36.11M | -46.40M | -40.56M | -56.05M | -70.69M | -63.02M | -69.71M | -61.80M | ||
| Depreciation and DepletionDep. & Depletion | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.02M | 0.03M | 0.03M | |||||||||
| Share-based CompensationStock Comp. | 1.86M | 5.95M | 1.99M | 2.48M | 2.59M | 2.60M | 2.58M | 1.50M | 1.43M | 1.61M | 1.68M | 1.83M | 1.84M | 1.93M | 2.29M | 3.31M | 3.71M | 3.59M | 13.36M | 2.55M | ||
| Cash from Discontinued OperationsCash from Discont. Ops | 101.00M | |||||||||||||||||||||
| Cash from OperationsCash from Ops. | -2.02M | -7.45M | -14.19M | -20.76M | -9.35M | -11.60M | -9.02M | -12.16M | -9.25M | -12.34M | -14.95M | -27.89M | -25.28M | -48.47M | -38.14M | -54.53M | -44.54M | -58.79M | -66.29M | -55.56M | ||
| Depreciation, Depletion & Amortization | ||||||||||||||||||||||
| Depreciation & Amortization (CF)Dep. & Amort. | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M | 0.33M | 0.37M | 0.32M | 0.38M | 0.40M | 0.72M | 0.78M | 0.72M | 0.84M | 0.90M | ||
| Change in Working Capital | ||||||||||||||||||||||
| Change in Account PayablesChange Payables | 0.21M | 0.81M | 2.25M | -3.03M | 0.27M | -0.80M | 3.57M | 0.53M | -0.96M | -1.57M | 1.65M | 1.66M | 5.57M | -1.72M | 3.01M | 5.07M | 8.20M | 4.27M | -6.17M | -6.34M | ||
| Change in Accured ExpensesChange Accured Exp. | 2.10M | 1.68M | -1.35M | -0.11M | 1.90M | 2.24M | -3.95M | -0.67M | 1.42M | 2.87M | -2.81M | 1.69M | 2.11M | 4.17M | -1.56M | -1.81M | 12.86M | -6.90M | 7.12M | 3.79M | ||
| Other Working Capital ChangesOther WC Changes | 0.02M | 1.38M | 0.85M | 2.82M | -0.63M | -0.30M | -1.10M | 1.51M | -1.27M | 7.22M | 0.83M | 8.18M | -1.49M | 5.37M | 1.70M | 1.87M | -0.27M | -1.27M | 10.10M | -6.51M | ||
| Investing Activities | ||||||||||||||||||||||
| Capital ExpendituresCapex | 0.01M | 0.02M | 0.02M | -2.00 | 1.00 | 0.28M | 0.21M | 0.13M | 0.18M | 0.04M | ||||||||||||
| Cash from Investing ActivitiesCash from Investing | -0.01M | -0.02M | -0.02M | 2.00 | -42.23M | 9.90M | 19.65M | 12.68M | -174.38M | 116.87M | -28.80M | -87.74M | 58.28M | -147.33M | 56.25M | 88.25M | 88.40M | -29.91M | 0.10M | 0.32M | ||
| Financing Activities | ||||||||||||||||||||||
| Cash from Financing ActivitiesCash from Financing | 0.50M | 15.00M | 15.00M | 104.69M | 0.00M | 451.29M | 28.42M | 50.98M | 0.18M | 0.15M | 73.12M | 0.48M | 72.39M | 30.64M | 234.62M | |||||||
| Change in Capital Stock | ||||||||||||||||||||||
| Net Preferred Shares Issued and RepurchasedNet Pref. Shares Issued | 0.50M | 0.00M | ||||||||||||||||||||
| Net Equity Issued and RepurchasedNet Equity Issued | -1.00 | 0.00M | -0.00M | 0.00M | 451.29M | 31.17M | 52.54M | 0.09M | 72.39M | 6.01M | 44.31M | |||||||||||
| Additional items | ||||||||||||||||||||||
| Exchange Rate EffectFX Effect | -0.00M | 0.00M | -0.01M | -0.05M | 0.07M | -0.01M | -535.00 | -0.14M | 0.01M | 0.06M | 0.05M | -0.02M | -0.33M | 0.42M | -0.09M | 1.39M | -0.28M | 0.09M | -0.48M | 0.03M | ||
| Change in Cash | -1.53M | 7.53M | 0.80M | 83.87M | -51.50M | -1.70M | 10.62M | 451.66M | -183.62M | 133.00M | 7.27M | -115.65M | 32.86M | -195.23M | 91.14M | 35.12M | 44.05M | -16.22M | -36.03M | 179.41M | ||
| Free Cash FlowFCF | -2.03M | -7.47M | -14.20M | -20.76M | -9.35M | -11.60M | -9.02M | -12.16M | -9.25M | -12.63M | -15.16M | -27.89M | -25.41M | -48.65M | -38.17M | -54.53M | -44.54M | -58.79M | -66.29M | -55.56M | ||
| Net Cash FlowNCF | -1.53M | 7.53M | 0.80M | 83.92M | -51.58M | -1.69M | 10.62M | 451.80M | -183.63M | 132.94M | 7.23M | -115.63M | 33.19M | -195.65M | 91.23M | 33.72M | 44.34M | -16.31M | -35.54M | 179.39M |
Pull MoonLake Immunotherapeutics's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=MLTX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "MLTX", "statement": "CF", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=MLTX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();